Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2025 08:45 ET | Source: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.
April 03, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making.
April 02, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
March 21, 2025 16:30 ET | Source: Immuneering Corporation

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Corporation Announces Grant of Inducement Award
March 20, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 04, 2025 07:09 ET | Source: Transparency Market Research

PD-1 Inhibitor Drugs Market Surges with Expanding Immunotherapy Applications, Set to Cross $201.5 Billion by 2035 | Latest Report by TMR

Wilmington, Delaware, United States, Transparency Market Research Inc. – , March 04, 2025 (GLOBE NEWSWIRE) -- The Global PD-1 Inhibitor Drugs Market, valued at US$ 41.4 billion in 2024, is set for...
December 12, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 11, 2024 07:00 ET | Source: Immunocore Holdings plc

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
November 27, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference

Next Page keyboard_arrow_right